This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To characterize the specificity of anti-GAD65 antibodies in patients with stiff person syndrome (SPS), quantify antibody titers, and examine antibody production within the CNS.
Methods: The authors studied 18 patients with SPS and positive serum immunoreactivity to gamma-aminobutyric acid (GABA)-ergic neurons. The reactivity of serum and CSF to purified GAD antigen was examined by Western blots, and the anti-GAD65 antibody titers in serum and CSF were quantified by ELISA and compared with 70 disease controls (49 with other autoimmune disorders and 11 with insulin-dependent diabetes mellitus). The intrathecal synthesis of anti-GAD65 IgG was calculated, and the functional significance of the antibodies was examined by measuring the GABA levels in the CSF.
Results: The serum and CSF of all selected patients with SPS had high anti-GAD65 titers (from 7.0 to 215 μg/mL in serum and from 92 to 2500 ng/mL in CSF) and immunoreacted strongly with recombinant GAD65 on Western blots and with GABA-ergic neurons on rat cerebellum. Among controls, only the serum of eight patients with insulin-dependent diabetes mellitus had low anti-GAD65 antibody titers (from 200 to 1760 ng/mL) but no reactivity to recombinant GAD65. The CSF showed oligoclonal IgG bands in 10 (67%) of 15 patients and an increased anti-GAD65-specific IgG index in 11 (85%) of 13. The mean level of GABA in the CSF was lower in patients with SPS than in controls.
Conclusions: In patients with SPS, there is marked intrathecal antibody response against neuronal GAD65 epitopes, indicating a clonal B cell activation in the CNS. Anti-GAD65 antibodies at high titers, when confirmed with immunoblots, are highly specific for SPS and appear to impair GABA synthesis.
- Received March 1, 2001.
- Accepted April 24, 2001.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity
Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy
Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies